Koichi Ohshima
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (24)
Acceleration of glycolysis is a common trait of cancer. A key metabolite, lactate, is typically secreted from cancer cells because its accumulation is toxic. Here, we report that a viral oncogene, HTLV-1 bZIP factor (HBZ), bimodally upregulates TAp73 to promote lactate excretion from adult T-cell leukemia-lymphoma (ATL) cells. HBZ protein binds to EZH2 and reduces its occupancy of the TAp73 promoter. Meanwhile, HBZ RNA activates TAp73 transcription via the BATF3-IRF4 machinery. TAp73 upregulates the lactate transporters MCT1 and MCT4. Inactivation of TAp73 leads to intracellular accumulation of lactate, inducing cell death in ATL cells. Furthermore, TAp73 knockout diminishes the development of inflammation in HBZ-transgenic mice. An MCT1/4 inhibitor, syrosingopine, decreases the growth of ATL cells in vitro and in vivo . MCT1/4 expression is positively correlated with TAp73 in many cancers, and MCT1/4 upregulation is associated with dismal prognosis. Activation of the TAp73–MCT1/4 pathway could be a common mechanism contributing to cancer metabolism. Significance: An antisense gene encoded in HTLV-1, HBZ, reprograms lactate metabolism and epigenetic modification by inducing TAp73 in virus-positive leukemic cells. A positive correlation between TAp73 and its target genes is also observed in many other cancer cells, suggesting that this is a common mechanism for cellular oncogenesis. This article is featured in Selected Articles from This Issue, p. 337
Year:
2024
Extranodal NK/T-cell lymphoma (ENKTCL) is an Epstein–Barr virus (EBV)–related neoplasm with male dominance and a poor prognosis. A better understanding of the genetic alterations and their functional roles in ENKTCL could help improve patient stratification and treatments. In this study, we performed a comprehensive genetic analysis of 178 ENKTCL cases to delineate the landscape of mutations, copy number alterations (CNA), and structural variations, identifying 34 driver genes including six previously unappreciated ones, namely, HLA-B , HLA-C , ROBO1 , CD58 , POT1 , and MAP2K1 . Among them, CD274 (24%) was the most frequently altered, followed by TP53 (20%), CDKN2A (19%), ARID1A (15%), HLA-A (15%), BCOR (14%), and MSN (14%). Chromosome X losses were the most common arm-level CNAs in females (∼40%), and alterations of four X-linked driver genes ( MSN , BCOR , DDX3X , and KDM6A ) were more frequent in males and females harboring chromosome X losses. Among X-linked drivers, MSN was the most recurrently altered, and its expression was lost in approximately one-third of cases using immunohistochemical analysis. Functional studies of human cell lines showed that MSN disruption promoted cell proliferation and NF-κB activation. Moreover, MSN inactivation increased sensitivity to NF-κB inhibition in vitro and in vivo . In addition, recurrent deletions were observed at the origin of replication in the EBV genome (6%). Finally, by integrating the 34 drivers and 19 significant arm-level CNAs, nonnegative matrix factorization and consensus clustering identified two molecular groups with different genetic features and prognoses irrespective of clinical prognostic factors. Together, these findings could help improve diagnostic and therapeutic strategies in ENKTCL. Significance: Integrative genetic analyses and functional studies in extranodal NK/T-cell lymphoma identify frequent disruptions of X-linked drivers, reveal prognostic molecular subgroups, and uncover recurrent MSN alterations that confer sensitivity to NF-κB inhibition.
Year:
2024
Extranodal NK/T-cell lymphoma (ENKTCL) is an Epstein–Barr virus (EBV)–related neoplasm with male dominance and a poor prognosis. A better understanding of the genetic alterations and their functional roles in ENKTCL could help improve patient stratification and treatments. In this study, we performed a comprehensive genetic analysis of 178 ENKTCL cases to delineate the landscape of mutations, copy number alterations (CNA), and structural variations, identifying 34 driver genes including six previously unappreciated ones, namely, HLA-B , HLA-C , ROBO1 , CD58 , POT1 , and MAP2K1 . Among them, CD274 (24%) was the most frequently altered, followed by TP53 (20%), CDKN2A (19%), ARID1A (15%), HLA-A (15%), BCOR (14%), and MSN (14%). Chromosome X losses were the most common arm-level CNAs in females (∼40%), and alterations of four X-linked driver genes ( MSN , BCOR , DDX3X , and KDM6A ) were more frequent in males and females harboring chromosome X losses. Among X-linked drivers, MSN was the most recurrently altered, and its expression was lost in approximately one-third of cases using immunohistochemical analysis. Functional studies of human cell lines showed that MSN disruption promoted cell proliferation and NF-κB activation. Moreover, MSN inactivation increased sensitivity to NF-κB inhibition in vitro and in vivo . In addition, recurrent deletions were observed at the origin of replication in the EBV genome (6%). Finally, by integrating the 34 drivers and 19 significant arm-level CNAs, nonnegative matrix factorization and consensus clustering identified two molecular groups with different genetic features and prognoses irrespective of clinical prognostic factors. Together, these findings could help improve diagnostic and therapeutic strategies in ENKTCL. Significance: Integrative genetic analyses and functional studies in extranodal NK/T-cell lymphoma identify frequent disruptions of X-linked drivers, reveal prognostic molecular subgroups, and uncover recurrent MSN alterations that confer sensitivity to NF-κB inhibition.
Year:
2024
Generation of GD2-CARrejTs. A, Schema, generation of GD2-CARrejTs. T-iPSCs established from LMP2-specific CTL clones were transduced with lentiviral GD2-CAR and GD2-CAR-iPSCs were differentiated into GD2-CARrejTs. B, Flow cytometric analysis of GD2-2840z-CARTs and GD2-CARrejTs to evaluate CAR transgene expression and LMP2 antigen specificity. Histogram in blue, fluorescence minus one (FMO) control. Histogram in red, GD2-2840z-CARTs and GD2-CARrejTs. The plots represent three independent experiments. C, Intracellular perforin and granzyme B marking, GD2-2840z-CARTs and GD2-CARrejTs (red). Histogram in blue, FMO control. The plots represent three independent experiments. D, CBA for measuring cytokines (IFNγ, TNF, and IL2) produced by effector T cells (GD2-2840z-CARTs and GD2-CARrejTs) after 24 hours of coculture with SCLC-J1. Error bars represent ± SEM. E, Representative flow cytometrogram of memory phenotype (CD45RA and CD62 L population) among GD2-2840-CARTs and GD2-CARrejTs. F, In vitro 51 Cr assays of GD2-2840z-CARTs, GD2-CARrejTs, and control T cells against SCLC cell lines. Error bars represent ± SD. Data represent three independent triplicate experiments. G, RTCA continuous graphical output of tumor proliferation indices up to 40 hours for H69 cells cocultured with control T cells, GD2-2840z-CARTs, and GD2-CARrejTs and for tumor only; E:T ratio uniformly 1:1. Data were plotted and are shown as mean ±SD. Data represent three independent triplicate experiments. H, RTCA continuous graphical output of tumor proliferation indices up to 100 hours for H446 cells cocultured with control T cells, GD2-2840z-CARTs, and GD2-CARrejTs and for tumor only; E:T ratio uniformly 1:1. Data were plotted and are shown as mean ±SD. Data represent three independent triplicate experiments.
Year:
2024
Blockade of TIGIT and PD-1 augments cytotoxicity of GD2 2840z-CARTs. A, Schema of immune-regulatory mechanism of T cells against SCLC. B, Flow cytometric analysis of TIGIT and CD226 expression on GD2-2840z-CARTs and GD2-CARrejTs. The plots represent independent triplicate experiments. C, Flow cytometric analysis of CD155 expression on H69, H446, and SCLC-J1 (red). Histogram in blue, fluorescence minus one (FMO) control. The histograms represent independent triplicate experiments. D, Flow cytometric analysis of PD-L1 expression on GD2-expressing tumor cell lines (H69, H446, and SCLC-J1; red). Histogram in blue, FMO control. The histograms represent independent triplicate experiments. E, RTCA continuous graphical output of tumor proliferation indices up to 80 hours alone and in coculture with GD2-2840z-CARTs with/without anti-TIGIT (aTIGIT) and/or anti-PD-1 antibodies (aPD-1). Data were plotted and are shown as mean ± SD. Data represent three independent triplicate experiments. F, Schema of immune-regulatory mechanism of GD2-2840z-CARTs and GD2-CARrejTs against SCLC.
Year:
2024
Generation of GD2-CARrejTs. A, Schema, generation of GD2-CARrejTs. T-iPSCs established from LMP2-specific CTL clones were transduced with lentiviral GD2-CAR and GD2-CAR-iPSCs were differentiated into GD2-CARrejTs. B, Flow cytometric analysis of GD2-2840z-CARTs and GD2-CARrejTs to evaluate CAR transgene expression and LMP2 antigen specificity. Histogram in blue, fluorescence minus one (FMO) control. Histogram in red, GD2-2840z-CARTs and GD2-CARrejTs. The plots represent three independent experiments. C, Intracellular perforin and granzyme B marking, GD2-2840z-CARTs and GD2-CARrejTs (red). Histogram in blue, FMO control. The plots represent three independent experiments. D, CBA for measuring cytokines (IFNγ, TNF, and IL2) produced by effector T cells (GD2-2840z-CARTs and GD2-CARrejTs) after 24 hours of coculture with SCLC-J1. Error bars represent ± SEM. E, Representative flow cytometrogram of memory phenotype (CD45RA and CD62 L population) among GD2-2840-CARTs and GD2-CARrejTs. F, In vitro 51 Cr assays of GD2-2840z-CARTs, GD2-CARrejTs, and control T cells against SCLC cell lines. Error bars represent ± SD. Data represent three independent triplicate experiments. G, RTCA continuous graphical output of tumor proliferation indices up to 40 hours for H69 cells cocultured with control T cells, GD2-2840z-CARTs, and GD2-CARrejTs and for tumor only; E:T ratio uniformly 1:1. Data were plotted and are shown as mean ±SD. Data represent three independent triplicate experiments. H, RTCA continuous graphical output of tumor proliferation indices up to 100 hours for H446 cells cocultured with control T cells, GD2-2840z-CARTs, and GD2-CARrejTs and for tumor only; E:T ratio uniformly 1:1. Data were plotted and are shown as mean ±SD. Data represent three independent triplicate experiments.
Year:
2024
Generation of GD2-CARTs. A, GD2 expression by NSCLC cell line (negative control) and by four SCLC cell lines (red), with isotype control (blue). The plots represent three independent experiments. B, Schema, lentiviral GD2-CAR-vectors containing Ubc promoter. CAR contains an scFv derived from heavy (VH) and light chain (VL) variable regions of 14G2a mAb. TM, transmembrane. Each CAR has a costimulatory domain (highlighted in red): GD2-2840z, CD28 and OX40; GD2-28z, CD28; and GD2-BBz, 4-1BB. The constructs contain the cleavable 2A-like sequence and mCherry. C, Flow cytometric analysis, GD2-CAR transgene expression in GD2-2840z-CARTs, GD2-28z-CARTs, and GD2-BBz-CARTs (red). Fluorescence minus one (FMO) control (blue). The histogram represents three independent experiments. D, Flow cytometric analysis, expression of LAG-3, PD-1, and TIM-3 on day 12 after transduction. Error bars represent ± SD. Data represent triplicate experiments. *, P P P E, In vitro 51 Cr release assay of GD2-2840z-CARTs, GD2-28z-CARTs, and GD2-BBz-CARTs (effectors) against GD2 + tumor cells (NK-YS). Error bars represent ± SD. Data represent triplicate experiments. F, In vitro 51 Cr release assay of GD2-2840z-CARTs against GD2 + SCLC. Error bars represent ± SD. Data represent three independent triplicate experiments. G, Flow cytometric analysis, MFI of GD2 on GD2-expressing tumors. Error bars represent ± SD. The bars represent triplicate experiments. H, In vitro 51 Cr release assay of GD2-2840z-CARTs against SCLC cell lines. Error bars represent ± SD. Data represent triplicate experiments.
Year:
2024
Supplementary Figure S4 presents flow cytometric analysis of PD-1, TIGIT, and CD226 expression on GD2-2840z-CARTs and GD2-CARrejTs after coculture with SCLC-J1 cells, based on three independent experiments. It also features real-time cell analysis (RTCA) showing tumor proliferation indices over 80 hours in various conditions: alone, in coculture with GD2-CARrejTs, and control T cells, with and without anti-TIGIT and anti-PD-1 antibodies. The data illustrate the effect of these treatments on tumor growth.
Year:
2024
Supplementary Figure S2 showcases the functional and phenotypic analysis of GD2-CARTs and GD2-CARrejTs, including cytokine production (IL-4, IL-6, IL-10, and IL-17A) through cytometric bead assays, flow cytometry gating strategies, memory phenotype subsets, CAR transgene expression, and CD4/8 ratios.
Year:
2024
Robust tumor suppressive effect of GD2-CARrejTs in vivo. A, Graphical abstract of in vivo experiment. H446 cells labeled with FFluc/GFP were intravenously injected into NOG mice (1 × 10 6 cells/mouse) 4 days before treatment. Mice treated with GD2-2840z-CARTs and GD2-CARrejTs were treated every 2 weeks (three doses). B, Bioluminescence imaging of mice engrafted with H446 cells in three groups: no treatment group (control group, n = 10), GD2-2840z-CARTs group ( n = 7), and GD2-CARrejTs group ( n = 7). Images of all mice from each group of three independent experiments are shown. C, Tumor burden of each mouse is shown, comparing the in vivo efficacy of GD2-2840z-CARTs and GD2-CARrejTs. Bioluminescence kinetics of all mice from each group of three independent experiments are shown: no treatment group (control group, n = 10), GD2-2840z-CARTs group ( n = 7), and GD2-CARrejTs group ( n = 7). D, Quantitation of tumor burden on day 35 is shown: no treatment group ( n = 8), GD2-2840z-CARTs group ( n = 7), and GD2-CARrejTs group ( n = 7). ****, P E, Kaplan–Meier curves representing percentage survival of groups: no treatment group ( n = 10), GD2-2840z-CARTs group ( n = 7), and GD2-CARrejTs group ( n = 7). ***, P P F, Copy numbers of GD2-CAR transduced T cells in mouse treated with GD2-2840z-CARTs and GD2-CARrejTs on day 35. Error bars represent ± SD. The plots represent three independent experiments. G, Photomicrographs, representative hematoxylin and eosin–stained sections of liver of SCLC-bearing mouse in each group; no treatment, GD2-2840z-CART treatment, and GD2-CARrejT treatment (top row). Infiltrates are bracketed. Human CD3 + T-cell infiltrates in liver (bottom row). CD3 + T cells are stained in brown (black arrowhead). 4x, 40x: Objective lens. Scale bars, each 20 µm.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (26)
Junji Koya
Senior Staff Scientist
National Cancer Center Research Institute
Felipe Suarez
Professor
Université Paris-Saclay
Akshay Joshi
University College London
Vahid Asnafi
-
Yamada Kyohei
Assistant professor
Kurume University
Seishi Ogawa
Kyoto University
Satoshi Yamazaki
Prof
University of Tokyo
Keisuke Kataoka
Chief
National Cancer Center Research Institute
Miki Ando
Juntendo University Graduate School of Medicine
Jean‐Marie Michot
-
Sumito Shingaki
New York University
Kenichi Tsujita
Professor of Medicine
Kumamoto University
Hiroaki Miyoshi
Professor
Kurume University
Isabelle André
Université Paris Descartes
Yozo Nakazawa
-
Yasunori Kogure
Senior Researcher
National Cancer Center Research Institute
Azusa Tanaka
University of Tokyo
Gandhi Damaj
Professor, M.D. Head of departement
University Hospital
Kazuhisa Takahashi
Professor
Juntendo University Graduate School of Medicine
Yuichiro Arima
Kumamoto University
Laurence de Leval
Director of the Institute of Pathology / Professor of Pathology
Lausanne University Hospital
Sachiko Tsukita
-
Masao Matsuoka
Kumamoto University
Hiromitsu Nakauchi
Distinguished University Professor
Tokyo Medical and Dental University
Koji Izutsu
Chief, Department of Hematology
National Cancer Center Hospital
Yuki Saito
National Cancer Center Research Institute
Make your next move.
Prepare your application
Review drafts before you send them.